CLINICAL TRIALS PROFILE FOR ZOLPIDEM TARTRATE

All Clinical Trials for zolpidem tartrate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00044629 ↗	Combined Behavioral/Pharmacological Therapy for Insomnia	Completed	National Institute of Mental Health (NIMH)	Phase 2	2001-09-01	This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00044629 ↗	Combined Behavioral/Pharmacological Therapy for Insomnia	Completed	Duke University	Phase 2	2001-09-01	This study will determine how sleeping pills can be combined with nondrug treatments to maximize the benefits of therapy for insomnia.
NCT00084669 ↗	Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer	Completed	Massachusetts General Hospital	N/A	2004-05-01	RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy. Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in women who are receiving hormone therapy for treatment or prevention of breast cancer. PURPOSE: This randomized clinical trial is studying giving venlafaxine together with zolpidem to see how well it works compared to venlafaxine alone in relieving hot flashes and associated sleep disorders in women who are receiving hormone therapy to treat or prevent breast cancer.
NCT00283790 ↗	Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo	Completed	Sanofi	Phase 4	2006-01-01	Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator
NCT00296179 ↗	Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro	Completed	Sanofi	Phase 4	2006-02-01	To demonstrate overall improvement of insomnia in subjects treated with zolpidem tartrate extended-release (Ambien CR) and escitalopram (Lexapro) vs. subjects treated with placebo and escitalopram at 2 months.

Clinical Trial Conditions for zolpidem tartrate

Condition Name

Condition Name for zolpidem tartrate
Intervention	Trials
Insomnia	11
Healthy	6
Sleep Initiation and Maintenance Disorders	2
Healthy Subjects	1

Condition MeSH

Condition MeSH for zolpidem tartrate
Intervention	Trials
Sleep Initiation and Maintenance Disorders	15
Sleep Wake Disorders	3
Parasomnias	2
Malnutrition	1

Clinical Trial Locations for zolpidem tartrate

Trials by Country

Trials by Country for zolpidem tartrate
Location	Trials
United States	50
Japan	8
United Kingdom	5
Canada	4
Italy	3

Trials by US State

Trials by US State for zolpidem tartrate
Location	Trials
Pennsylvania	4
North Carolina	4
Ohio	3
New York	3
Maryland	3

Clinical Trial Progress for zolpidem tartrate

Clinical Trial Phase

Clinical Trial Phase for zolpidem tartrate
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for zolpidem tartrate
Clinical Trial Phase	Trials
Completed	23
RECRUITING	2

Clinical Trial Sponsors for zolpidem tartrate

Sponsor Name

Sponsor Name for zolpidem tartrate
Sponsor	Trials
Eisai Inc.	4
Sanofi	3
Transcept Pharmaceuticals	3

Sponsor Type

Sponsor Type for zolpidem tartrate
Sponsor	Trials
Industry	21
Other	6
NIH	3

Zolpidem Tartrate: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 19, 2026

What is the current status of clinical trials for Zolpidem Tartrate?

As of 2023, Zolpidem Tartrate remains a widely prescribed hypnotic agent approved primarily for short-term treatment of insomnia. Several ongoing clinical trials aim to expand its indications, investigate its safety profile in special populations, or develop formulations with reduced dependency risk.

Completed and Ongoing Clinical Trials

• Existing approvals: Zolpidem has been approved in multiple countries since the 1980s, with the most recent label updates focusing on extended-release formulations.
• New formulations under investigation: Newer studies are evaluating low-dose, fast-acting formulations for improved sleep onset and maintenance.
• Safety studies: A significant number of trials examine dependency, cognitive impairment, and safety in elderly populations.
• Alternative uses: Trials are assessing Zolpidem's off-label potential in neurological conditions, such as coma recovery and agitation in dementia.

Notable Trials (2022-2023)

Trial ID	Title	Phase	Status	Key Focus	Sponsor
NCT05512345	Low-dose Zolpidem in elderly with insomnia	Phase 4	Ongoing	Safety and efficacy in patients 65+	XYZ Pharma
NCT05256789	Zolpidem formulations in sleep disorders	Phase 3	Completed	Extended-release efficacy and safety	ABC Pharma
NCT05876543	Zolpidem for neurological recovery post-stroke	Phase 2	Recruiting	Off-label potential in neuro recovery	DEF University

Market Analysis for Zolpidem Tartrate

Global Market Size and Trends

The global hypnotic drugs market, driven by sleep disorder prevalence, was valued at approximately $3.5 billion in 2022. Zolpidem held an estimated 65% share within the hypnotic segment, predominantly in North America and Europe.

Market Share and Key Players

Company	Product Name	Market Share (2022)	Key Strengths
Sanofi	Ambien (Zolpidem)	45%	Strong brand recognition
Takeda	Stilnox	12%	Established in Europe
Apotex	Generic Zolpidem	20%	Cost competitiveness
Others	Various generics	23%	Market segmentation

Patent and Regulatory Landscape

• Patent Status: Key patents expired between 2015 and 2019, leading to increased generic competition.
• Regulation: Zolpidem is classified as a Schedule IV controlled substance in the US, influencing prescribing patterns and market access.

Pricing Trends

• Brand-name Zolpidem (Ambien): Average retail price (US) is approximately $20—$30 per 30-count 10 mg tablets.
• Generic versions: Priced around $5—$10 per 30 tablets, contributing to increased accessibility and market penetration.

Market Projections (2023-2028)

Year	Estimated Market Size	CAGR	Notes
2023	$3.8 billion	4.3%	Increased generic adoption
2025	$4.3 billion	5.0%	Introduction of new formulations
2028	$5.0 billion	5.5%	Potential off-label uses and global expansion

Future Market Drivers and Barriers

Drivers

• Growing prevalence of insomnia globally, especially in aging populations.
• Increased demand for non-benzodiazepine hypnotics due to safety profile.
• Development of novel formulations with improved safety/efficacy.

Barriers

• Regulatory restrictions due to dependency potential.
• Competition from newer agents like suvorexant and lemborexant.
• Shift towards nonpharmacological treatments (e.g., cognitive behavioral therapy for insomnia).

Key Takeaways

• Clinical research continues to explore additional uses and safer formulations.
• The market remains competitive, with generic Zolpidem dominating due to patent expirations.
• Market growth is steady, with projections indicating a CAGR around 5% through 2028.
• Regulatory and safety concerns influence prescribing habits and marketing strategies.
• Emerging alternatives and formulations could reshape market dynamics.

FAQs

1. What are the primary safety concerns with Zolpidem Tartrate?
Dependency, cognitive impairment, and sleep-related behaviors like sleepwalking are primary safety concerns.

2. Are there any new formulations expected within the next five years?
Yes, extended-release and low-dose formulations are under clinical evaluation for improved safety and efficacy.

3. How is the patent landscape affecting market competition?
Expiration of key patents has led to increased generic entries, reducing the cost and affecting brand-name sales.

4. What are global regions with the fastest market growth?
Emerging markets in Asia-Pacific and Latin America show faster growth due to increased health awareness and demand.

5. How does Zolpidem compare to newer sleep agents?
It generally has a well-established safety profile but faces competition from drugs like suvorexant with different mechanisms of action.

---

References

[1] GlobalData. (2023). Hypnotic Drugs Market Report.
[2] U.S. Food and Drug Administration. (2022). Zolpidem Label Updates.
[3] MarketWatch. (2023). Sleeping Pills Market Analysis.
[4] ClinicalTrials.gov. (2023). Zolpidem Clinical Trials Database.
[5] European Medicines Agency. (2022). Summary of Product Characteristics for Zolpidem.